AbbVie (ABBV) Cash from Operations (2012 - 2026)
AbbVie (ABBV) posted quarterly Cash from Operations of 3829000000.0 for Q1 2026, up 134.19% year-over-year from 1635000000.0 in Q1 2025, and down 26.62% quarter-over-quarter from 5218000000.0 in Q4 2025.
AbbVie (ABBV) Cash from Operations (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Cash from Operations for 15 consecutive years, with 3829000000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 134.19% year-over-year to 3829000000.0; the TTM figure through Mar 2026 stood at 21224000000.0 (up 29.41% YoY), while the FY2025 annual figure was 19030000000.0, up 1.19% from the prior year.
- Cash from Operations fell to 3829000000.0 in Q1 2026 per ABBV's latest filing, from 5218000000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 7602000000.0 in Q3 2022 and bottomed at 1635000000.0 in Q1 2025.
- Historically, Cash from Operations has averaged 5261588235.29 across 5 years, with a median of 5153000000.0 in 2025.
- Annual changes were most pronounced in 2024 — Cash from Operations sank 64.06% — and 2026, when it soared 134.19%.
- AbbVie's Cash from Operations stood at 7428000000.0 in 2022, then sank by 36.01% to 4753000000.0 in 2023, then soared by 48.29% to 7048000000.0 in 2024, then retreated by 25.96% to 5218000000.0 in 2025, then fell by 26.62% to 3829000000.0 in 2026.
- Business Quant data shows ABBV's Cash from Operations at 3829000000.0 in Q1 2026, 5218000000.0 in Q4 2025, and 7024000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 8.62 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.44 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 5.37 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.88 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 4.00 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.57 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 835.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.44 Bn |
| Jun 30, 2026 | 3.44 Bn |
| Mar 31, 2026 | 3.83 Bn |
| Mar 31, 2026 | 3.83 Bn |
| Dec 31, 2025 | 5.22 Bn |
| Dec 31, 2025 | 5.22 Bn |
| Sep 30, 2025 | 7.02 Bn |
| Sep 30, 2025 | 7.02 Bn |
| Jun 30, 2025 | 5.15 Bn |
| Jun 30, 2025 | 5.15 Bn |
| Mar 31, 2025 | 1.64 Bn |
| Mar 31, 2025 | 1.64 Bn |
| Dec 31, 2024 | 7.05 Bn |
| Dec 31, 2024 | 7.05 Bn |
| Sep 30, 2024 | 5.45 Bn |
| Sep 30, 2024 | 5.45 Bn |
| Jun 30, 2024 | 2.27 Bn |
| Jun 30, 2024 | 2.27 Bn |
| Mar 31, 2024 | 4.04 Bn |
| Mar 31, 2024 | 4.04 Bn |